In conclusion, in this study, we propose that Cdk4 is an important regulator of GBM stem-like phenotype and invasive capacity, addressing how the Notch inhibitors and RSV combination could therefore be a rational therapeutic strategy to target Cdk4 and to eliminate GSCs, further preventing tumor recurrence in GBM patients. This evidence concerns the gene CDK4 and glioblastoma.